Zaineb Abdelkafi

Dr. Zaineb Abdelkafi

Institut Pasteur de Tunis
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
ZAZaineb Abdelkafi
Zaineb Abdelkafi
IAImen Aissa
Imen Aissa
MMMaram Morjen
Maram Morjen
NKNadia Kharrat
Nadia Kharrat
MAMohamed El Ayeb
Mohamed El Ayeb
NMNaziha Marrakchi
Naziha Marrakchi

4 June 2021 in Toxins
Verified
Journal Article
Open access
PDF file
Ayoub LAFNOUNEAyoub LAFNOUNE
Ayoub LAFNOUNE
SLSu-Yeon Lee
Su-Yeon Lee
JHJin-Yeong Heo
Jin-Yeong Heo
IGImane Gourja
Imane Gourja
Bouchra DarkaouiBouchra Darkaoui
Bouchra Darkaoui
NONaoual Oukkache
Naoual Oukkache
Hepatocellular carcinoma (HCC) is the most common primary liver cancer in adults, the fifth most common malignancy worldwide and the third leading cause of cancer related death. An alternative to the surgical treatments and drugs, such as sorafenib, commonly used in medicine is necessary to overcome this public health problem. In this study, we determine the anticancer effect on HCC of Moroccan cobra Naja haje venom and its fraction obtained by gel filtration chromatography against Huh7.5 cancer cell line. Cells were grown together with WI38 human fibroblast cells, LX2 human hepatic stellate cell line, and human endothelial cells (HUVEC) in MCTS (multi-cellular tumor spheroids) models. The hepatotoxicity of venom and its fractions were also evaluated using the normal hepatocytes cell line (Fa2N-4 cells). Our results showed that an anti HCC activity of Moroccan cobra Naja haje venom and, more specifically, the F7 fraction of gel filtration chromatography exhibited the greatest anti-hepatocellular carcinoma effect by decreasing the size of MCTS. This effect is associated with a low toxicity against normal hepatocytes. These results strongly suggest that the F7 fraction of Moroccan cobra Naja haje venom obtained by gel filtration chromatography possesses the ability to inhibit cancer cells proliferation. More research is needed to identify the specific molecule(s) responsible for the anticancer effect and investigate their mechanism of action.

15 December 2021 in Molecules
Verified
Journal Article
Open access
PDF file
DADorra Aissaoui
Dorra Aissaoui
MSMohamed-Chiheb Saada
Mohamed-Chiheb Saada
WMWassim Moslah
Wassim Moslah
MPMarie Potier-Cartereau
Marie Potier-Cartereau
ALAude Lemettre
Aude Lemettre
NSNajet Srairi-Abid
Najet Srairi-Abid
Glioblastoma is an aggressive cancer, against which medical professionals are still quite helpless, due to its resistance to current treatments. Scorpion toxins have been proposed as a promising alternative for the development of effective targeted glioblastoma therapy and diagnostic. However, the exploitation of the long peptides could present disadvantages. In this work, we identified and synthetized AaTs-1, the first tetrapeptide from Androctonus australis scorpion venom (Aa), which exhibited an antiproliferative effect specifically against human glioblastoma cells. Both the native and synthetic AaTs-1 were endowed with the same inhibiting effect on the proliferation of U87 cells with an IC50 of 0.56 mM. Interestingly, AaTs-1 was about two times more active than the anti-glioblastoma conventional chemotherapeutic drug, temozolomide (TMZ), and enhanced its efficacy on U87 cells. AaTs-1 showed a significant similarity with the synthetic peptide WKYMVm, an agonist of a G-coupled formyl-peptide receptor, FPRL-1, known to be involved in the proliferation of glioma cells. Interestingly, the tetrapeptide triggered the dephosphorylation of ERK, p38, and JNK kinases. It also enhanced the expression of p53 and FPRL-1, likely leading to the inhibition of the store operated calcium entry. Overall, our work uncovered AaTs-1 as a first natural potential FPRL-1 antagonist, which could be proposed as a promising target to develop new generation of innovative molecules used alone or in combination with TMZ to improve glioblastoma treatment response. Its chemical synthesis in non-limiting quantity represents a valuable advantage to design and develop low-cost active analogues to treat glioblastoma cancer.

1 October 2014 in Toxicon
Verified
Journal Article
Closed access
ZAZaineb Abdelkafi
Zaineb Abdelkafi
JJJed Jebali
Jed Jebali
HOHoucemeddine Othman
Houcemeddine Othman
MMMaram Morjen
Maram Morjen
IAImen Aissa
Imen Aissa
NMNaziha Marrakchi
Naziha Marrakchi

26 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
WMWassim Moslah
Wassim Moslah
DADorra Aissaoui
Dorra Aissaoui
SASoioulata Aboudou
Soioulata Aboudou
ZAZaineb Abdelkafi
Zaineb Abdelkafi
MPMarie Potier-Cartereau
Marie Potier-Cartereau
NSNajet Srairi-Abid
Najet Srairi-Abid
Glioblastoma is the most aggressive and invasive form of central nervous system tumors due to the complexity of the intracellular mechanisms and molecular alterations involved in its progression. Unfortunately, current therapies are unable to stop its neoplastic development. In this context, we previously identified and characterized AaTs-1, a tetrapeptide (IWKS) from Androctonus autralis scorpion venom, which displayed an anti-proliferative effect against U87 cells with an IC50 value of 0.57 mM. This peptide affects the MAPK pathway, enhancing the expression of p53 and altering the cytosolic calcium concentration balance, likely via FPRL-1 receptor modulation. In this work, we designed and synthesized new dendrimers multi-branched molecules based on the sequence of AaTs-1 and showed that the di-branched (AaTs-1-2B), tetra-branched (AaTs-1-4B) and octo-branched (AaTs-1-8B) dendrimers displayed 10- to 25-fold higher effects on the proliferation of U87 cells than AaTs-1. We also found that the effects of the newly designed molecules are mediated by the enhancement of the ERK1/2 and AKT phosphorylated forms and by the increase in p53 expression. Unlike AaTs-1, AaTs-1-8B and especially AaTs-1-4B affected the migration of the U87 cells. Thus, the multi-branched peptide synthesis strategy allowed us to make molecules more active than the linear peptide against the proliferation of U87 glioblastoma cells.

16 December 2021 in Toxins
Verified
Journal Article
Open access
PDF file
ZAZaineb Abdelkafi
Zaineb Abdelkafi
IEInes ELBINI
Ines ELBINI
SSSoumaya Souid
Soumaya Souid
JJjed jebali
jed jebali
RDRaoudha Doghri
Raoudha Doghri
NMNaziha Marrakchi
Naziha Marrakchi
Snake venom proteins, which are responsible for deadly snakebite envenomation, induce severe injuries including neurotoxicity, myotoxicity, cardiotoxicity, hemorrhage, and the disruption of blood homeostasis. Yet, many snake-venom proteins have been developed as potential drugs for treating human diseases due to their pharmacological effects. In this study, we evaluated the use of, an L-amino acid oxidase isolated from Cerastes cerastes snake venom CC-LAAO, as a potential anti-glioblastoma drug, by investigating its in vivo and in vitro pharmacological effects. Our results showed that acute exposure to CC-LAAO at 1 and 2.5 µg/mL does not induce significant toxicity on vital organs, as indicated by the murine blood parameters including aspartate transaminase (AST), alanine transaminase (ALT), lactate dehydrogenase (LDH) activities, and creatinine levels. The histopathological examination demonstrated that only at high concentrations did CC-LAAO induce inflammation and necrosis in several organs of the test subjects. Interestingly, when tested on human glioblastoma U87 cells, CC-LAAO induced a dose-dependent apoptotic effect through the H2O2 generated during the enzymatic reaction. Taken altogether, our data indicated that low concentration of CC-LAAO may be safe and may have potential in the development of anti-glioblastoma agents.